PhotoMedex Offers Free Seminar for Psoriasis Patients: “A Win for Your Skin in the Daily Fight Against Psoriasis”

PhotoMedex, Inc. (Nasdaq: PHMD) a leading provider of advanced dermatology, clinical skincare and medical laser products, is hosting a free seminar in Indianapolis, IN on November 17, 2009. The seminar, “A Win for Your Skin in the Daily Fight Against Psoriasis with XTRAC^® Excimer Lasers,” is open to the public and will feature three prominent local physicians (from the Dermatology Group LLC and The Dermatology Center of Indiana, LLC) explaining the New XTRAC Velocity Laser treatments for psoriasis sufferers. The XTRAC Velocity Laser is used in the treatment of mild, moderate, AND severe psoriasis.

Guest Speakers: Kenneth Dawes, M.D., Scott Fretzin, M.D., and Scott T. Guenther, M.D.

Seminar overview: Numerous clinical studies have shown the dramatic difference that “non-surgical” laser light can make in treating skin conditions such as psoriasis. The patented XTRAC Excimer Laser from PhotoMedex targets only the affected areas, sparing healthy surrounding skin. It is clinically proven to be very safe, painless and highly effective.

Our guest speakers, all leading dermatologists, will explain the laser therapy and cover the many benefits the XTRAC excimer laser treatment system offers psoriasis sufferers, including:

• No negative systemic side effects
• No “black box” warning for cancer or serious infections
• Yes, long lasting relief, typically several months free of symptoms
• Yes, reimbursed by Medicare and most major private insurance plans

Complimentary refreshments will be provided for attendees.

Who should attend: People who suffer from mild, moderate and especially severe psoriasis should learn how the XTRAC Velocity Excimer Laser therapy system is the right treatment for them. We know the devastating effects psoriasis can have on an individual’s self esteem, which is why we also encourage attendance by family members and friends of those afflicted with psoriasis.

Date: Tuesday, November 17, 2009 from 6:30 p.m. to 7:30 p.m.

Location:		Indianapolis Downtown Marriott
		350 West Maryland Street
		Indianapolis, IN 46225
		(317) 822 - 3500

Registration: The seminar is offered free of charge by PhotoMedex and discount coupons for parking will be provided. Attendees are invited to register by calling the XTRAC TeleCare Center at (866) 404-3752. Space is limited, and this seminar is expected to fill up quickly, so early registration is strongly advised to ensure a seat.

About PhotoMedex

PhotoMedex develops proprietary excimer laser and fiber optic systems and techniques directed toward dermatological applications, with FDA 510(k) clearances to market the XTRAC^® laser system for the treatment of psoriasis, vitiligo, atopic dermatitis and leukoderma. The Company is a leader in the development, manufacturing and marketing of medical laser products and services. PhotoMedex also develops and markets products based on DNA Repair enzymes and its patented, clinically proven Copper Peptide technology for skin health, hair care and wound care. PhotoMedex sells directly to dermatologists, plastic and cosmetic surgeons, and salons. ProCyte brands include Neova^®, Ti-Silc^®, VitalCopper^®, Simple Solutions^® and AquaSanté^®.

In addition, as a result of the recent merger with PhotoTherapeutics, PhotoMedex now researches, develops and manufactures non-laser light devices for the treatment of clinical and aesthetic dermatological conditions and adds the Omnilux™ products to its portfolio. The Omnilux products incorporate a new technology based on narrowband Light Emitting Diodes (LEDs) to treat a wide range of dermatological conditions including acne, photodamage, and skin rejuvenation.

This press release includes forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on managements’ current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.